May 19, 2020 / 8:37 PM / 16 days ago

BRIEF-Eiger Biopharmaceuticals Announces FDA Acceptance Of NDA For Filing With Priority Review Of Zokinvy

May 19 (Reuters) - Eiger BioPharmaceuticals Inc:

* EIGER BIOPHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NDA FOR FILING WITH PRIORITY REVIEW OF ZOKINVY™ (LONAFARNIB) FOR TREATMENT OF PROGERIA AND PROGEROID LAMINOPATHIES

* EIGER BIOPHARMACEUTICALS INC - FDA IS NOT CURRENTLY PLANNING TO HOLD AN ADVISORY COMMITTEE MEETING TO DISCUSS ZOKINVY APPLICATION

* EIGER BIOPHARMACEUTICALS INC - GRANTED PDUFA DATE OF NOVEMBER 20, 2020 FOR ZOKINVY

* EIGER BIOPHARMACEUTICALS - ACCEPTED NDA FOR ACCELERATED REVIEW OF ZOKINVY FOR TREATMENT OF PROGERIA AND PROGEROID LAMINOPATHIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below